Figure F-15 is titled “PTSD symptom reduction (any measure) for exposure therapy compared with control, by type of comparator: Sensitivity analysis including present centered therapy.” The figure displays a forest plot reporting the standardized mean difference in PTSD symptoms stratified by exposure therapy compared to waitlist, exposure therapy compared to usual care, and exposure therapy compared to present centered therapy. The plot depicts greater reductions in PTSD symptoms for patients treated with exposure therapy than waitlist (5 trials, standardized mean difference −1.16, 95% CI −1.40 to −0.91, I2 = 0.0%), usual care (2 trials, standardized mean difference −1.79, 95% CI −2.43 to −1.15, I2 = 0.0%), or present centered therapy (1 trial, standardized mean difference −0.26, 95% CI −0.50 to −0.03,). The overall analysis favored exposure therapy (standardized mean difference −1.17, 95% CI −1.63 to −0.71, I2 = 83.3%).

Figure F-15PTSD symptom reduction (any measure) for exposure therapy compared with control, by type of comparator: Sensitivity analysis including present centered therapy

Timing of outcome assessment: 8 weeks (Basoglu, 2007), 12 weeks (Foa, 2005), 9 weeks (Foa, 1999), 6 weeks (Resick, 2002), 4.5 weeks (Rothbaum, 2005), “post-treatment” or 8 to 15 weeks (Asukai, 2010), 9 to 15 weeks (Nacasch), 10 weeks (Schnurr 2007).

From: Appendix F, Meta-Analysis

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.